212 related articles for article (PubMed ID: 37144745)
1. Targeted therapeutic strategies for melanoma.
Zhang S; Xie R; Zhong A; Chen J
Chin Med J (Engl); 2023 Dec; 136(24):2923-2930. PubMed ID: 37144745
[TBL] [Abstract][Full Text] [Related]
2.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
3. Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets.
Flaherty KT
Clin Exp Metastasis; 2012 Oct; 29(7):841-6. PubMed ID: 22661223
[TBL] [Abstract][Full Text] [Related]
4. A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.
Sun W; Xu Y; Yan W; Wang C; Hu T; Luo Z; Zhang X; Liu X; Chen Y
Cancer Med; 2023 Aug; 12(15):15945-15954. PubMed ID: 37403699
[TBL] [Abstract][Full Text] [Related]
5. Improving patient outcomes to targeted therapies in melanoma.
Eroglu Z; Smalley KS; Sondak VK
Expert Rev Anticancer Ther; 2016 Jun; 16(6):633-41. PubMed ID: 27137746
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
Delyon J; Lebbe C; Dumaz N
Curr Opin Oncol; 2020 Mar; 32(2):79-84. PubMed ID: 31833955
[TBL] [Abstract][Full Text] [Related]
7. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
11. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
12. Clinical Trials in Melanoma: Margins, Lymph Nodes, Targeted and Immunotherapy.
Sharon CE; Beasley GM; Karakousis GC
Surg Oncol Clin N Am; 2023 Jan; 32(1):47-63. PubMed ID: 36410921
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
[TBL] [Abstract][Full Text] [Related]
14. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapy in Advanced Melanoma With Rare
Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
[TBL] [Abstract][Full Text] [Related]
16. Principles of Targeted Therapy for Melanoma.
Sun J; Carr MJ; Khushalani NI
Surg Clin North Am; 2020 Feb; 100(1):175-188. PubMed ID: 31753111
[TBL] [Abstract][Full Text] [Related]
17. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
18. Emerging targeted therapies for melanoma.
Johnson DB; Pollack MH; Sosman JA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in melanoma.
Kudchadkar RR; Smalley KS; Glass LF; Trimble JS; Sondak VK
Clin Dermatol; 2013; 31(2):200-8. PubMed ID: 23438383
[TBL] [Abstract][Full Text] [Related]
20. A review of binimetinib for the treatment of mutant cutaneous melanoma.
Koelblinger P; Dornbierer J; Dummer R
Future Oncol; 2017 Aug; 13(20):1755-1766. PubMed ID: 28587477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]